Scholarlink

Purpose of Review <p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including Semaglutide, are promising therapeutic options for glycemic control and weight management in type 2 diabetes (T2DM) and post-transplant diabetes mellitus (PTDM). However, evidence of their use in kidney transplant recipients remains limited. This literature review evaluated the clinical efficacy, outcomes, and safety data of Semaglutide in kidney transplant recipients with PTDM. Key studies assessed glycemic control, weight management, insulin dependence, graft function, and adverse effects.</p> Recent Findings <p>We included several studies, and Semaglutide demonstrated significantly improved HbA1c levels, reduced weight, and decreased insulin requirements in PTDM patients. Clinical trials and cohort studies reported HbA1c reductions of 1–1.2% and weight loss up to 8.8&#xa0;kg over 12–18&#xa0;months. Metabolic benefits were achieved without adverse effects on graft function or significant changes in immunosuppressive therapy levels. Gastrointestinal side effects were the most common adverse events, leading to therapy discontinuation in some cases. No significant incidence of graft rejection was observed.</p> Summary <p>Semaglutide demonstrates substantial potential in managing PTDM among kidney transplant recipients, offering improvements in metabolic control and stable graft function. However, the evidence is primarily based on small-scale studies with limited follow-up. Large-scale, prospective trials are needed to confirm its long-term safety and efficacy. Until then, clinicians should individualize therapy and monitor closely for adverse effects.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Use of Semaglutide in Diabetes Care Post Renal Transplantation

  • 期刊论文

  • 发表日期：

    2025年4月2日

查看全文
  • Omar Buraykan Alluhayyan,
  • Faisal Mohammed Almutawa,
  • Yousef Ibrahim Alghamdi,
  • Khalid Abdullah Alyousef,
  • Khalid Ali Altaleb,
  • Hala Abdulaziz AlGhamdi,
  • Moeber Mahzari

摘要

Purpose of Review

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including Semaglutide, are promising therapeutic options for glycemic control and weight management in type 2 diabetes (T2DM) and post-transplant diabetes mellitus (PTDM). However, evidence of their use in kidney transplant recipients remains limited. This literature review evaluated the clinical efficacy, outcomes, and safety data of Semaglutide in kidney transplant recipients with PTDM. Key studies assessed glycemic control, weight management, insulin dependence, graft function, and adverse effects.

Recent Findings

We included several studies, and Semaglutide demonstrated significantly improved HbA1c levels, reduced weight, and decreased insulin requirements in PTDM patients. Clinical trials and cohort studies reported HbA1c reductions of 1–1.2% and weight loss up to 8.8 kg over 12–18 months. Metabolic benefits were achieved without adverse effects on graft function or significant changes in immunosuppressive therapy levels. Gastrointestinal side effects were the most common adverse events, leading to therapy discontinuation in some cases. No significant incidence of graft rejection was observed.

Summary

Semaglutide demonstrates substantial potential in managing PTDM among kidney transplant recipients, offering improvements in metabolic control and stable graft function. However, the evidence is primarily based on small-scale studies with limited follow-up. Large-scale, prospective trials are needed to confirm its long-term safety and efficacy. Until then, clinicians should individualize therapy and monitor closely for adverse effects.